Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000084.xml
Synthesis 2008(24): 3957-3962
DOI: 10.1055/s-0028-1083241
DOI: 10.1055/s-0028-1083241
PAPER
© Georg Thieme Verlag
Stuttgart ˙ New York
Novel Bioconjugates of Aminolevulinic Acid with Nucleosides
Further Information
Received
2 September 2008
Publication Date:
01 December 2008 (online)
Publication History
Publication Date:
01 December 2008 (online)
Abstract
Esters and amino acid derivatives of 5-aminolevulinic acid (ALA) are efficient prodrugs for the production of protoporphyrin IX (PpIX), which has been used in photodynamic cancer therapy (PDT). The synthesis of novel bioconjugates combining ALA with adenosine and thymidine is reported. The novel bioconjugates have been made using a robust methodology. The new class of prodrugs contains one, two, or three ALA per molecule. Preliminary cell tests in human cancer cell lines indicate that the thymidine conjugate of ALA is an efficient prodrug for PDT.
Key words
nucleosides - esterification - porphyrins - photochemistry - anticancer agent
-
1a
Hopper C. Lancet Oncol. 2000, 1: 212 -
1b
Dougherty TJ. J. Clin. Laser Med. Surg. 2002, 20: 3 -
1c
Dolmans DEJGJ.Fukumura D.Jain RK. Nat. Rev. Cancer. 2003, 3: 380 -
1d
Alison RR.Downie GH.Cuenca R.Hu X.-H.Childs CJH.Sibata CH. Photodiagn. Photodyn. Ther. 2004, 1: 27 -
2a
Finsen NR. Br. Med. J. 1903, 1297 -
2b
Finsen NR. J. Am. Med. Assoc. 1903, 41: 1207 -
2c
Von Tappeiner H.Jodlbauer A.Lehmann H. Arch. Klin. Med. 1905, 82: 217 -
2d
Meyer-Betz F. Dtsch. Arch. Klein. Med. 1913, 112: 476 -
3a
Solban N.Rizvi I.Hasan T. Lasers Surg. Med. 2006, 38: 522 -
3b
Brown SB.Brown EA.Walker I. Lancet Oncol. 2004, 5: 497 -
3c
Bakri SJ.Kaiser PK. Expert. Opin. Pharmacother. 2004, 5: 195 -
3d
Haimovici R.Kramer M.Miller JW.Hasan T.Flotte TJ.Schomacker KT.Gargoudas ES. Curr. Eye Res. 1997, 2: 83 -
3e
Husain D.Miller JW.Kenney AG.Michaud N.Flotte TJ.Gargoudas ES. Ophthalmology 1997, 104: 1242 -
3f
Allison BA.Pritchard PH.Richter AM.Levy JG. Photochem. Photobiol. 1990, 52: 501 -
3g
Richter AM.Waterfield E.Ashok KJ.Sternberg ED.Dolphin D.Levy JG. Photochem. Photobiol. 1990, 52: 495 -
4a
Fukuda H.Casas A.Batlle A. Int. J. Biochem. Cell Biol. 2005, 37: 272 -
4b
Lopez RFV.Lange N.Guy R.Bentley MVLB. Adv. Drug Deliv. Rev. 2004, 56: 77 -
4c
Fotinos N.Campo MA.Popowycz F.Gurny R.Lange N. Photochem. Photobiol. 2006, 82: 994 -
5a
Kloek J.Beijersbergen van H. Photochem. Photobiol. 1996, 64: 994 -
5b
Peng Q.Moan J.Warloe T.Iani V.Steen HB.Bjorseth A.Nesland JM. J. Photochem. Photobiol. B 1996, 34: 95 -
6a
Kaliszewski M.Kwasny M.Kaminski J.Dabrowsky Z.Burdziakowska E. Acta Pol. Pharm. 2004, 61: 15 ; Chem. Abstr. 2004, 142, 204371 -
6b
Gadmar OB.Moan J.Scheie E.Ma L.-W.Peng Q. J. Photochem. Photobiol. B. 2002, 67: 187 -
6c
Bunke A.Zerbe O.Schmid H.Burmeister G.Merkle HP.Gander B. J. Pharm. Sci. 2000, 89: 1335 -
6d
Elfsson B.Walin I.Eksborg S.Rudaeus K.Ros AM.Ehrsson H. Eur. J. Pharm Sci. 1999, 7: 87 -
6e
Butler AR.George S. Tetrahedron 1992, 48: 7879 -
7a
Berger Y.Greppi A.Siri O.Neier R.Juillerat-Jeanneret L. J. Med. Chem. 2000, 43: 4738 -
7b
Berger Y.Ingrassia L.Neier R.Juillerat-Jeanneret L. Bioorg. Med. Chem. 2003, 11: 1343 -
7c
Rogers LMA.McGivern PG.Butler AR.MacRobert AJ.Eggleston IM. Tetrahedron 2005, 61: 6951 -
7d
Dixon MJ.Bourré L.MacRobert AJ.Eggleston IM. Bioorg. Med. Chem. Lett. 2007, 17: 4518 -
8a
Vallinayagam R.Schmitt F.Barge J.Wagnieres G.Wenger V.Neier R.Juillerat-Jeannerat L. Bioconj. Chem. 2008, 19: 821 -
8b
Vallinayagam R. Synthesis of Novel Prodrugs for Targeted Photodynamic Therapy, Ph.D. Thesis University of Neuchatel; Neuchatel: 2007. - 9
Vallinayagam R.Bertschy H.Berger Y.Wenger V.Neier R. Synthesis 2007, 3: 731 -
10a
Bonate PL.Arthaud L.Cantrell WR.Stephenson K.Secrist JA.Weitman S. Nat. Rev. Drug Discovery 2006, 5: 855 -
10b
Jacobsen KA.Gao Z.-G. Nat. Rev. Drug Discovery 2006, 5: 247 -
10c
Comin MJ.Pellegrinet SC.Rodriguez JB. ARKIVOC 2005, (xii): 205 -
11a
Chen P.Chien P.-Y.Khan AR.Sheikh S.Ali SM.Ahmad MU.Ahmad I. Anticancer Drugs 2006, 17: 53 -
11b
Wiebe LI. Braz. Arch. Biol. Technol. 2007, 50: 445 ; Chem. Abstr. 2007, 147, 40027 -
11c
Merighi S.Mirandola P.Varani K.Gessi S.Leung E.Baraldi PG.Tabrizi MA.Borea PA. Pharmacol. Ther. 2003, 100: 31 -
11d
Gessi S.Cattabriga E.Avitabile A.Gafa R.Lanza G.Cavazzini L.Bianchi N.Gambari R.Feo C.Liboni A.Gullini S.Leung E.Mac-Lennan S.Borea PA. Clin. Cancer. Res. 2004, 10: 5895 -
11e
Focher F.Spadari S. Curr. Cancer Drug Targets 2001, 1: 141 -
11f
Aghi M.Kramm CM.Chou T.-C.Breakefield XO.Chiocca EA. J. Natl. Cancer Inst. 1998, 90: 370 - 12
Moris F.Gotor V. J. Org. Chem. 1993, 58: 653 - 13
Garcia J.Fernandez S.Ferrero M.Sanghvi YS. J. Org. Chem. 2002, 67: 4513 -
14a
Lindgren M.Hallbrink M.Prochiantz A.Langel U. Trends Biotechnol. 2003, 21: 498 -
14b
Bayele HK.Ramaswamy C.Wilderspin AF.Srai KS.Toth I.Florence AT. J. Pharm. Sci. 2006, 95: 1227 -
14c
Kueltzo LA.Middaugh CR. J. Pharm. Sci. 2003, 92: 1754 - 15
Zhang J.Visser F.King KM.Baldwin SA.Young JD.Cass CE. Cancer Metastasis Rev. 2007, 26: 85 - 16
Schmitt F.Govindaswamy P.Süss-Fink G.Ang WH.Dyson PJ.Juillerat-Jeanneret L.Therrien B. J. Med. Chem. 2008, 51: 1811